Gefitinib

Gefitinib

Form: Oral Tablets:

Strength: 250 mg

Reference Brands: Iressa® (EU & US)

Category: Oncology Cancer Care

Gefitinib is a targeted oral therapy used in the treatment of advanced non-small cell lung cancer (NSCLC) with confirmed EGFR mutations. Marketed under the brand name Iressa®, Gefitinib is approved in the EU and US and is widely available as 250 mg tablets. It is an EGFR tyrosine kinase inhibitor that blocks signals promoting tumor cell growth and proliferation. Gefitinib is an essential product in oncology therapy protocols and is frequently used as a first-line treatment for eligible NSCLC patients. Ideal for B2B pharmaceutical distributors seeking high-demand oncology medications in global regulated markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Atezolizumab

Strength: 1200 mg/20 mL

Form: Intravenous infusion

Reference Brands: Tecentriq® (EU & US)

View Details Get Enquiry
Durvalumab

Strength: 120 mg/4 mL, 500 mg/10 mL

Form: Injection

Reference Brands: Imfinzi® (US & EU)

View Details Get Enquiry
Sunitinib

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Form: Tablet

Reference Brands: Sutent® (EU & US)

View Details Get Enquiry
Ifosfamide

Strength: 1 g/vial,2 g/vial, 3 g/vial

Form: Injection

Reference Brands: Ifex® (US), Holoxan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.